Drugs / MW33
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04533048 | Aug → Nov 2020 | COVID-19 | Mabwell (Shanghai) Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04627584 | Dec 2020 → May 2021 | COVID-19 | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MW33 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04627584 ↗ |
| Known as | MW33 injection | “Combination Product: MW33 injection” NCT04627584 ↗ |
| Modality | Monoclonal antibody | “fully humanized IgG1κ monoclonal neutralizing antibody” PMID 34346827 ↗ Dec 2021 |
| Route | Intravenous | “infused with MW33 over 60 ± 15 min” PMID 34346827 ↗ Dec 2021 |